Which has higher earnings and valuation, OMER or CRSP?

Omeros has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros $38.42M 34.44 -$3.35M $1.28 14.28 CRISPR Therapeutics $3.51M 1,424.73 -$581.60M -$4.76 N/A

Is OMER or CRSP more profitable?

Omeros has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% CRISPR Therapeutics -3,368.72% -24.39% -18.25%

Does the media favor OMER or CRSP?

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Omeros. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 4 mentions for Omeros. Omeros' average media sentiment score of 1.11 beat CRISPR Therapeutics' score of 0.85 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, OMER or GRFS?

Grifols has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros $38.42M 34.44 -$3.35M $1.28 14.28 Grifols $8.51B 0.60 $454.82M $0.19 39.74

Is OMER or GRFS more profitable?

Grifols has a net margin of 5.54% compared to Omeros' net margin of 0.00%. Grifols' return on equity of 6.21% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Grifols 5.54% 6.21% 2.39%

Which has preferable earnings and valuation, OMER or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Omeros. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros $38.42M 34.44 -$3.35M $1.28 14.28 Parabilis Medicines $148K 30,783.09 N/A N/A N/A

Is OMER or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Parabilis Medicines N/A N/A N/A

Does the media refer more to OMER or PBLS?

In the previous week, Omeros had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for Omeros and 3 mentions for Parabilis Medicines. Omeros' average media sentiment score of 1.11 beat Parabilis Medicines' score of 0.92 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACAD or OMER?

In the previous week, Omeros had 1 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 4 mentions for Omeros and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.21 beat Omeros' score of 1.11 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, OMER or CELC?

Omeros has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros $38.42M 34.44 -$3.35M $1.28 14.28 Celcuity N/A N/A -$177.04M -$4.30 N/A

Is OMER or CELC more profitable?

Omeros' return on equity of -164.92% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Celcuity N/A -350.78% -41.54%

Does the media favor OMER or CELC?

In the previous week, Celcuity had 1 more articles in the media than Omeros. MarketBeat recorded 5 mentions for Celcuity and 4 mentions for Omeros. Celcuity's average media sentiment score of 1.24 beat Omeros' score of 1.11 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Omeros (OMER) Competitors

$18.28 -0.31 (-1.67%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$18.34 +0.06 (+0.33%)

As of 09/11/2026 07:56 PM Eastern

Compare

OMER vs. CRSP, GRFS, PBLS, ACAD, and CELC

Should you buy Omeros stock or one of its competitors? Omeros's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Grifols (GRFS), Parabilis Medicines (PBLS), ACADIA Pharmaceuticals (ACAD), and Celcuity (CELC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Omeros compare to CRISPR Therapeutics?

Omeros (NASDAQ:OMER) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

48.8% of Omeros shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Omeros. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 4 mentions for Omeros. Omeros' average media sentiment score of 1.11 beat CRISPR Therapeutics' score of 0.85 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros presently has a consensus target price of $38.00, indicating a potential upside of 107.88%. CRISPR Therapeutics has a consensus target price of $68.06, indicating a potential upside of 31.58%. Given Omeros' stronger consensus rating and higher possible upside, research analysts clearly believe Omeros is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Omeros has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Omeros has a beta of 2.6, suggesting that its share price is 160% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

Omeros has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$38.42M	34.44	-$3.35M	$1.28	14.28
CRISPR Therapeutics	$3.51M	1,424.73	-$581.60M	-$4.76	N/A

Summary

Omeros beats CRISPR Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Omeros compare to Grifols?

Omeros (NASDAQ:OMER) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Omeros currently has a consensus price target of $38.00, indicating a potential upside of 107.88%. Grifols has a consensus price target of $10.00, indicating a potential upside of 32.45%. Given Omeros' stronger consensus rating and higher possible upside, equities analysts plainly believe Omeros is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Grifols has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$38.42M	34.44	-$3.35M	$1.28	14.28
Grifols	$8.51B	0.60	$454.82M	$0.19	39.74

In the previous week, Omeros had 3 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Omeros and 1 mentions for Grifols. Grifols' average media sentiment score of 1.44 beat Omeros' score of 1.11 indicating that Grifols is being referred to more favorably in the news media.

Company	Overall Sentiment
Omeros	Positive
Grifols	Positive

Omeros has a beta of 2.6, meaning that its stock price is 160% more volatile than the broader market. Comparatively, Grifols has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

48.8% of Omeros shares are held by institutional investors. 10.5% of Omeros shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Grifols has a net margin of 5.54% compared to Omeros' net margin of 0.00%. Grifols' return on equity of 6.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Grifols	5.54%	6.21%	2.39%

Summary

Omeros beats Grifols on 11 of the 17 factors compared between the two stocks.

How does Omeros compare to Parabilis Medicines?

Omeros (NASDAQ:OMER) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Parabilis Medicines has lower revenue, but higher earnings than Omeros.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$38.42M	34.44	-$3.35M	$1.28	14.28
Parabilis Medicines	$148K	30,783.09	N/A	N/A	N/A

In the previous week, Omeros had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for Omeros and 3 mentions for Parabilis Medicines. Omeros' average media sentiment score of 1.11 beat Parabilis Medicines' score of 0.92 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines' return on equity of 0.00% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Parabilis Medicines	N/A	N/A	N/A

48.8% of Omeros shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Omeros currently has a consensus price target of $38.00, indicating a potential upside of 107.88%. Parabilis Medicines has a consensus price target of $41.67, indicating a potential upside of 12.98%. Given Omeros' higher probable upside, research analysts clearly believe Omeros is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Omeros beats Parabilis Medicines on 7 of the 11 factors compared between the two stocks.

How does Omeros compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Omeros (NASDAQ:OMER) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

In the previous week, Omeros had 1 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 4 mentions for Omeros and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.21 beat Omeros' score of 1.11 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Omeros' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Omeros	N/A	-164.92%	69.41%

ACADIA Pharmaceuticals currently has a consensus target price of $34.36, indicating a potential upside of 23.47%. Omeros has a consensus target price of $38.00, indicating a potential upside of 107.88%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

ACADIA Pharmaceuticals has higher revenue and earnings than Omeros. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.48	$391M	$2.22	12.54
Omeros	$38.42M	34.44	-$3.35M	$1.28	14.28

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Omeros has a beta of 2.6, suggesting that its stock price is 160% more volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats Omeros on 10 of the 17 factors compared between the two stocks.

How does Omeros compare to Celcuity?

Omeros (NASDAQ:OMER) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

48.8% of Omeros shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Omeros has a beta of 2.6, suggesting that its share price is 160% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Omeros' return on equity of -164.92% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Celcuity	N/A	-350.78%	-41.54%

Omeros has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$38.42M	34.44	-$3.35M	$1.28	14.28
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Omeros presently has a consensus target price of $38.00, suggesting a potential upside of 107.88%. Celcuity has a consensus target price of $154.55, suggesting a potential upside of 85.20%. Given Omeros' higher possible upside, research analysts clearly believe Omeros is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Celcuity had 1 more articles in the media than Omeros. MarketBeat recorded 5 mentions for Celcuity and 4 mentions for Omeros. Celcuity's average media sentiment score of 1.24 beat Omeros' score of 1.11 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omeros beats Celcuity on 9 of the 15 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMER vs. The Competition

Export

Metric	Omeros	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.35B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	14.28	14.25	275.24	25.29
Price / Sales	34.44	1,473.06	655.99	98.94
Price / Cash	9.93	106.68	77.04	51.44
Price / Book	-10.69	15.12	10.33	6.20
Net Income	-$3.35M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-3.54%	-4.34%	-3.32%	-2.35%
1 Month Performance	33.33%	-0.02%	-0.41%	-2.77%
1 Year Performance	340.48%	40.64%	19.21%	7.63%

Omeros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMER Omeros	4.208 of 5 stars	$18.28 -1.7%	$38.00 +107.9%	+335.2%	$1.35B	$38.42M	14.28	210	Positive News
CRSP CRISPR Therapeutics	2.3557 of 5 stars	$55.79 flat	$68.06 +22.0%	-7.5%	$5.39B	$3.51M	N/A	460	Gap Down
GRFS Grifols	4.762 of 5 stars	$7.80 flat	$10.00 +28.2%	-24.8%	$5.31B	$8.51B	41.05	25,247
PBLS Parabilis Medicines	2.6144 of 5 stars	$40.42 flat	$41.67 +3.1%	N/A	$4.99B	N/A	N/A	N/A	Positive News
ACAD ACADIA Pharmaceuticals	4.3742 of 5 stars	$28.02 flat	$34.36 +22.6%	+15.0%	$4.83B	$1.07B	12.62	510	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMER) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omeros (OMER) Competitors

OMER vs. CRSP, GRFS, PBLS, ACAD, and CELC

How does Omeros compare to CRISPR Therapeutics?

Summary

How does Omeros compare to Grifols?

Summary

How does Omeros compare to Parabilis Medicines?

Summary

How does Omeros compare to ACADIA Pharmaceuticals?

Summary

How does Omeros compare to Celcuity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omeros (OMER) Competitors

OMER vs. CRSP, GRFS, PBLS, ACAD, and CELC

How does Omeros compare to CRISPR Therapeutics?

Do institutionals & insiders have more ownership in OMER or CRSP?

Does the media favor OMER or CRSP?

Do analysts prefer OMER or CRSP?

Is OMER or CRSP more profitable?

Which has more volatility and risk, OMER or CRSP?

Which has higher earnings and valuation, OMER or CRSP?

Summary

How does Omeros compare to Grifols?

Do analysts recommend OMER or GRFS?

Which has better earnings & valuation, OMER or GRFS?

Does the media refer more to OMER or GRFS?

Which has more volatility and risk, OMER or GRFS?

Do institutionals and insiders have more ownership in OMER or GRFS?

Is OMER or GRFS more profitable?

Summary

How does Omeros compare to Parabilis Medicines?

Which has preferable earnings and valuation, OMER or PBLS?

Does the media refer more to OMER or PBLS?

Is OMER or PBLS more profitable?

Do insiders & institutionals have more ownership in OMER or PBLS?

Do analysts recommend OMER or PBLS?

Summary

How does Omeros compare to ACADIA Pharmaceuticals?

Does the media favor ACAD or OMER?

Is ACAD or OMER more profitable?

Do analysts prefer ACAD or OMER?

Which has preferable valuation and earnings, ACAD or OMER?

Do insiders and institutionals believe in ACAD or OMER?

Which has more volatility and risk, ACAD or OMER?

Summary

How does Omeros compare to Celcuity?

Do insiders & institutionals hold more shares of OMER or CELC?

Which has more volatility & risk, OMER or CELC?

Is OMER or CELC more profitable?

Which has stronger earnings and valuation, OMER or CELC?

Do analysts prefer OMER or CELC?

Does the media favor OMER or CELC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools